These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 32805059)

  • 21. Practical guidelines for the management of toxic epidermal necrolysis and Stevens-Johnson syndrome.
    Fromowitz JS; Ramos-Caro FA; Flowers FP;
    Int J Dermatol; 2007 Oct; 46(10):1092-4. PubMed ID: 17910723
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravenous immunoglobulins for delayed wound healing associated with toxic epidermal necrolysis.
    Dequidt L; Darrigade AS; Camus T; Taieb A; Milpied B
    Eur J Dermatol; 2019 Apr; 29(2):229-231. PubMed ID: 30983592
    [No Abstract]   [Full Text] [Related]  

  • 23. Intravenous immunoglobulin in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a meta-analysis with meta-regression of observational studies.
    Barron SJ; Del Vecchio MT; Aronoff SC
    Int J Dermatol; 2015 Jan; 54(1):108-15. PubMed ID: 24697283
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravenous immunoglobulin prophylaxis for recurrent Stevens-Johnson syndrome.
    Hebert AA; Bogle MA
    J Am Acad Dermatol; 2004 Feb; 50(2):286-8. PubMed ID: 14726889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IVIG for the treatment of toxic epidermal necrolysis.
    Mittmann N; Chan BC; Knowles S; Shear NH
    Skin Therapy Lett; 2007 Feb; 12(1):7-9. PubMed ID: 17361314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vesicular eczema after intravenous immunoglobulin therapy for treatment of Stevens-Johnson syndrome.
    Young PK; Ruggeri SY; Galbraith S; Drolet BA
    Arch Dermatol; 2006 Feb; 142(2):247-8. PubMed ID: 16490861
    [No Abstract]   [Full Text] [Related]  

  • 27. IVIg in TEN: time to re-evaluate the efficacy of intravenous immunoglobulin in the management of toxic epidermal necrolysis.
    Walsh S; Creamer D
    Br J Dermatol; 2012 Aug; 167(2):230-1. PubMed ID: 22835022
    [No Abstract]   [Full Text] [Related]  

  • 28. Stevens-Johnson syndrome and toxic epidermal necrolysis: efficacy of intravenous immunoglobulin and a review of treatment options.
    Teo L; Tay YK; Liu TT; Kwok C
    Singapore Med J; 2009 Jan; 50(1):29-33. PubMed ID: 19224081
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rapid remission of Stevens-Johnson syndrome by combination therapy using etanercept and intravenous immunoglobulin and a review of the literature.
    Wang R; Zhong S; Tu P; Li R; Wang M
    Dermatol Ther; 2019 Jul; 32(4):e12832. PubMed ID: 30659711
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of toxic epidermal necrolysis in a coronavirus disease 2019 patient with recurrence of positive SARS-CoV-2 viral RNA.
    Tanaka A; Isei M; Kikuzawa C; Hinogami H; Nishida K; Gohma I; Ogawa Y
    J Dermatol; 2021 Mar; 48(3):e144-e145. PubMed ID: 33439527
    [No Abstract]   [Full Text] [Related]  

  • 31. Toxic epidermal necrolysis complicated by delayed mucosal healing and haemorrhagic mucositis.
    Dawe S; Bentley R; Creamer D
    Clin Exp Dermatol; 2003 Jul; 28(4):454-5. PubMed ID: 12823319
    [No Abstract]   [Full Text] [Related]  

  • 32. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature.
    Letko E; Papaliodis DN; Papaliodis GN; Daoud YJ; Ahmed AR; Foster CS
    Ann Allergy Asthma Immunol; 2005 Apr; 94(4):419-36; quiz 436-8, 456. PubMed ID: 15875523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stevens-Johnson syndrome and toxic epidermal necrolysis in Asian children.
    Koh MJ; Tay YK
    J Am Acad Dermatol; 2010 Jan; 62(1):54-60. PubMed ID: 19811851
    [TBL] [Abstract][Full Text] [Related]  

  • 34. COVID-19 infection increases the development of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective cohort analysis.
    Curtis KK; Dillan MM; Sharma TR; Piktel J
    J Am Acad Dermatol; 2024 Jun; 90(6):1300-1302. PubMed ID: 38423469
    [No Abstract]   [Full Text] [Related]  

  • 35. [Toxic epidermal necrolysis treated with human gamma globulin].
    Pulido-Díaz N; Angulo-Álvarez DM; López-Ibarra M
    Rev Med Inst Mex Seguro Soc; 2012; 50(1):59-62. PubMed ID: 22768819
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Toxic epidermal necrolysis treated with intravenous immunoglobulins].
    Corne P; Dereure O; Guilhou JJ; Jonquet O
    Rev Med Interne; 2001 May; 22(5):491-2. PubMed ID: 11402525
    [No Abstract]   [Full Text] [Related]  

  • 37. Profile and pattern of Stevens-Johnson syndrome and toxic epidermal necrolysis in a general hospital in Singapore: treatment outcomes.
    Tan SK; Tay YK
    Acta Derm Venereol; 2012 Jan; 92(1):62-6. PubMed ID: 21710108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of intravenous immunoglobulin in children with stevens-johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature.
    Metry DW; Jung P; Levy ML
    Pediatrics; 2003 Dec; 112(6 Pt 1):1430-6. PubMed ID: 14654625
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose of intravenous gammaglobulin in toxic epidermal necrolysis.
    Choo TL
    Singapore Med J; 2012 Mar; 53(3):219. PubMed ID: 22434299
    [No Abstract]   [Full Text] [Related]  

  • 40. Intravenous immunoglobulin efficacy on pembrolizumab induced severe toxic epidermal necrolysis.
    Kian W; Zemel M; Elobra F; Sharb AA; Levitas D; Assabag Y; Alguayn F; Yakobson A; Rouvinov K; Fuchs L
    Anticancer Drugs; 2022 Jan; 33(1):e738-e740. PubMed ID: 34321417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.